Immunological Effects of Ayahuasca in Humans

REFERENCES

• Andrade, E.N.; Brito, G.S.; Andrade, E.O.; Neves, E.S.; McKenna, D.; Cavalcante, J.W.; Okimura, L.; Grob, C. & Callaway, J.C. 2004. Farmacologia humana da hoasca: Estudos clínicos (avaliação clínica comparativa entre usuários do chá hoasca por longo prazo e controles; avaliação fisiológica dos efeitos agudos pós-ingestão do chá hoasca) [Human pharmacology of hoasca: Clinical studies (comparative clinical assessment between long-term consumers of the hoasca tea and controls; physiological assessment of acute effects after ingestion of the hoasca tea]. In: B.C. Labate & W.S. Araújo (Eds.) O Uso Ritual da Ayahuasca [The Ritual Use of Ayahuasca], 2nd ed. Campinas: Mercado de Letras.
   Google Scholar
• Barbosa, P.C.; Mizumoto, S.; Bogenschutz, M.P. & Strassman, R.J. 2012. Health status of ayahuasca users. Drug Testing & Analysis 4 (7–8): 601–09.
   PubMed Web of Science ®Google Scholar
• Bouso, J.C.; González, D.; Fondevila, S.; Cutchet, M.; Fernández, X.; Barbosa, P.C.R.; Alcázar-Córcoles, M.Á.; Araújo, W.S.; Barbanoj, M.J.; Fábregas, J.M. & Riba, J. 2012. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: A longitudinal study. PLoS ONE 7 (8): e42421.
   PubMed Web of Science ®Google Scholar
• Breznitz, S.; Ben-Zur, H.; Berzon, Y.; Weiss, D.W.; Levitan, G.; Tarcic, N.; Lischinsky, S.; Greenberg, A.; Levi, N. & Zinder, O. 1998. Experimental induction and termination of acute psychological stress in human volunteers: Effects on immunological, neuroendocrine, cardiovascular, and psychological parameters. Brain, Behavior, and Immunity 12 (1): 34–52.
   PubMed Web of Science ®Google Scholar
• Buckholtz, N.S. & Boggan, W.O. 1977. Inhibition by β-carbolines of monoamine uptake into a synaptosomal preparation: Structure-activity relationships. Life Sciences 20 (12): 2093–9.
   PubMed Web of Science ®Google Scholar
• Caligiuri, M.A. 2008. Human natural killer cells. Blood 112 (3): 461–9.
   PubMed Web of Science ®Google Scholar
• Callaway, J.C.; McKenna, D.J.; Grob, C.S.; Brito, G.S.; Raymon, L.P.; Poland, R.E.; Andrade, E.N.; Andrade, E.O. & Mash, D.C. 1999. Pharmacokinetics of Hoasca alkaloids in healthy humans. Journal of Ethnopharmacology 65 (3): 243–56.
   PubMed Web of Science ®Google Scholar
• Chaplin, D.D. 2010. Overview of the immune response. Journal of Allergy and Clinical Immunology 125 ( 2 Suppl 2): S3–23.
   PubMed Web of Science ®Google Scholar
• Davydova, S.M.; Cheido, M.A.; Gevorgyan, M.M. & Idova, G.V. 2010. Effects of 5-HT2A receptor stimulation and blocking on immune response. Bulletin of Experimental Biology and Medicine 150 (2): 219–21.
   PubMed Web of Science ®Google Scholar
• Dhabhar, F.S. 2009. Enhancing versus suppressive effects of stress on immune function: Implications for immunoprotection and immunopathology. Neuroimmunomodulation 16 (5): 300–17.
   PubMed Web of Science ®Google Scholar
• dos Santos, R.G. 2011. Ayahuasca: Physiological and subjective effects, comparison with d-amphetamine, and repeated dose assessment. Doctoral thesis, Universitat Autònoma de Barcelona, Barcelona, Spain. Available at: https://www.educacion.gob.es/teseo/mostrarRef.do?ref=959049.
   Google Scholar
• dos Santos, R.G. 2013a. Safety and side effects of ayahuasca in humans: An overview focusing on developmental toxicology. Journal of Psychoactive Drugs 45 (1): 68–78.
   PubMed Web of Science ®Google Scholar
• dos Santos, R.G. 2013b. A critical evaluation of reports associating ayahuasca with life-threatening adverse reactions. Journal of Psychoactive Drugs 45 (2): 179–88.
   PubMed Web of Science ®Google Scholar
• dos Santos, R.G.; Grasa, E.; Valle, M.; Ballester, M.R.; Bouso, J.C.; Nomdedéu, J.F.; Homs, R.; Barbanoj, M.J. & Riba, J. 2012. Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology 219 (4): 1039–53.
   PubMed Web of Science ®Google Scholar
• dos Santos, R.G.; Valle, M.; Bouso, J.C.; Nomdedéu, J.F.; Rodríguez-Espinosa, J.; McIlhenny, E.H.; Barker, S.A.; Barbanoj, M.J. & Riba, J. 2011. Autonomic, neuroendocrine and immunological effects of ayahuasca: A comparative study with d-amphetamine. Journal of Clinical Psychopharmacology 31 (6): 717–26.
   PubMed Web of Science ®Google Scholar
• Fábregas, J.M.; González, D.; Fondevila, S.; Cutchet, M.; Fernández, X.; Barbosa, P.C.; Alcázar-Córcoles, M.Á.; Barbanoj, M.J.; Riba, J. & Bouso, J.C. 2010. Assessment of addiction severity among ritual users of ayahuasca. Drug and Alcohol Dependence 111 (3): 25761.
   Web of Science ®Google Scholar
• Feld, M.; Goodman, J.R. & Guido, J.A. 1958. Clinical and laboratory observations on LSD-25. Journal of Nervous and Mental Disease 126 (2): 176–83.
   PubMed Web of Science ®Google Scholar
• Forrer, G.R. & Goldner, R.D. 1951. Experimental physiological studies with lysergic acid diethylamide (LSD-25). AMA Archives of Neurology and Psychiatry 65 (5): 581–8.
   PubMedGoogle Scholar
• Frecska, E.; Szabo, A.; Winkelman, M.J.; Luna, L.E. & McKenna, D.J. 2013. A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity. Journal of Neural Transmission 120 (9): 1295–303.
   PubMed Web of Science ®Google Scholar
• Friedman, E.M. & Irwin, M.R. 1997. Modulation of immune cell function by the autonomic nervous system. Pharmacology and Therapeutics 74 (1): 27–38.
   PubMed Web of Science ®Google Scholar
• Gomes, M.M.; Coimbra, J.B.; Clara, R.O.; Dörr, F.A.; Moreno, A.C.; Chagas, J.R.; Tufik, S.; Pinto, E. Jr.; Catalani, L.H. & Campa, A. 2014. Biosynthesis of N,N-dimethyltryptamine (DMT) in a melanoma cell line and its metabolization by peroxidases. Biochemical Pharmacology 88 (3): 393–401.
   PubMed Web of Science ®Google Scholar
• González-Maeso, J.; Ang, R.L.; Yuen, T.; Chan, P.; Weisstaub, N.V.; López-Giménez, J.F.; Zhou, M.; Okawa, Y.; Callado, L.F.; Milligan, G.; Gingrich, J.A.; Filizola, M.; Meana, J.J. & Sealfon, S.C. 2008. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452 (7183): 93–7.
   PubMed Web of Science ®Google Scholar
• Hanks, J.B. & González-Maeso, J. 2013. Animal models of serotonergic psychedelics. ACS Chemical Neuroscience 4 (1): 33–42.
   PubMed Web of Science ®Google Scholar
• Hasler, F.; Grimberg, U.; Benz, M.A.; Huber, T. & Vollenweider, F.X. 2004. Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study. Psychopharmacology 172 (2): 145–56.
   PubMed Web of Science ®Google Scholar
• Hintzen, A. & Passie, T. 2010. The Pharmacology of LSD: A Critical Review. New York: Oxford University Press.
   Google Scholar
• Hollister, L.E. & Sjoberg, B.M. 1964. Clinical syndromes and biochemical alterations following mescaline, lysergic acid diethylamide, psilocybin, and a combination of the three psychotomimetic drugs. Comprehensice Psychiatry 5: 170–8.
   PubMed Web of Science ®Google Scholar
• House, R.V.; Thomas, P.T. & Bhargava, H.N. 1994. Immunological consequences of in vitro exposure to lysergic acid diethylamide (LSD). Immunopharmacology and Immunotoxicology 16 (1): 23–40.
   PubMed Web of Science ®Google Scholar
• House, R.V.; Thomas, P.T. & Bhargava, H.N. 1995. Comparison of the hallucinogenic indole alkaloids ibogaine and harmaline for potential immunomodulatory activity. Pharmacology 51 (1): 56–65.
   PubMed Web of Science ®Google Scholar
• House, R.V.; Thomas, P.T. & Bhargava, H.N. 1997. Immunotoxicology of opioids, inhalants, and other drugs of abuse. NIDA Research Monographs 173: 175–200.
   PubMedGoogle Scholar
• Idova, G.; Davydova, S.; Alperina, E.; Cheido, M. & Devoino, L. 2008. Serotoninergic mechanisms of immunomodulation under different psychoemotional states: I. A role of 5-HT1A receptor subtype. International Journal of Neuroscience 118 (11): 1594–608.
   PubMed Web of Science ®Google Scholar
• Labate, B.C. & Jungaberle, H. (Eds.). 2011. The Internationalization of Ayahuasca. Zurich: Lit Verlag.
   Google Scholar
• Labate, B.C.; Rose, I.S. & dos Santos, R.G. 2009. Ayahuasca Religions: A Comprehensive Bibliography and Critical Essays. Santa Cruz, CA: Multidisciplinary Association for Psychedelic Studies.
   Google Scholar
• Lanier, L.L. 2008. Evolutionary struggles between NK cells and viruses. Nature Reviews: Immunology 8 (4): 259–68.
   PubMed Web of Science ®Google Scholar
• Luna, L.E. 2011. Indigenous and mestizo use of Ayahuasca: An overview. In: R.G. dos Santos (Ed.) The Ethnopharmacology of Ayahuasca. Trivandrum: Transworld Research Network. Available at: http://www.trnres.com/ebook/uploads/rafael/T_12998349951%20Rafael.pdf.
   Google Scholar
• McKenna, D.J., Luna, L.E. & Towers, G.N. 1995. Biodynamic constituents in ayahuasca admixture plants: An uninvestigated folk pharmacopeia. In: R.E. Schultes & S. von Reis (Eds.) Ethnobotany: Evolution of a Discipline. Portland, OR: Dioscorides Press.
   Google Scholar
• Moreno, J.L.; Holloway, T.; Albizu, L.; Sealfon, S.C. & González-Maeso, J. 2011. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neuroscience Letters 493 (3): 76–9.
   PubMed Web of Science ®Google Scholar
• Nau, F. Jr.; Yu, B.; Martin, D. & Nichols, C.D. 2013. Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo. PLoS One 8 (10): e75426.
   PubMed Web of Science ®Google Scholar
• Nichols, D.E. 2004. Hallucinogens. Pharmacology and Therapeutics 101 (2): 131–81.
   PubMed Web of Science ®Google Scholar
• Ott, J. 1994. Ayahuasca Analogues. Kennewick, WA: Natural Books Co.
   Google Scholar
• Pacifici, R.; Zuccaro, P.; Farré, M.; Pichini, S.; Di Carlo, S.; Roset, P.N.; Lopez, C.H.; Ortuño, J.; Segura, J.; Camí, J. & de la Torre, R. 2000. Immunomodulating activity of MDMA. Annals of the New York Academy of Sciences 914: 215–24.
   PubMed Web of Science ®Google Scholar
• Pacifici, R.; Zuccaro, P.; Hernandez López, C.; Pichini, S.; Di Carlo, S.; Farré, M.; Roset, P.N.; Ortuño, J.; Segura, J. & Torre, R.L. 2001. Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. Journal of Pharmacology and Experimental Therapeutics 296 (1): 207–15.
   PubMed Web of Science ®Google Scholar
• Palhano-Fontes, F.; Alchieri, J.C.; Oliveira, J.P.M.; Soares, B.L.; Hallak, J.E.C.; Galvao-Coelho, N. & de Araujo, D.B. 2014. The therapeutic potentials of ayahuasca in the treatment of depression. In: B.C. Labate & C. Cavnar (Eds.) The Therapeutic Use of Ayahuasca. Berlin/Heidelberg: Springer-Verlag.
   Google Scholar
• Passie, T.; Seifert, J.; Schneider, U. & Emrich, H.M. 2002. The pharmacology of psilocybin. Addiction Biology 7 (4): 357–64.
   PubMed Web of Science ®Google Scholar
• Riba, J. 2003. Human pharmacology of Ayahuasca. Doctoral thesis, Universitat Autònoma de Barcelona, Barcelona, Spain. Available at: http://www.tdx.cesca.es/TDX-0701104-165104/.
   Google Scholar
• Riba, J.; Romero, S.; Grasa, E.; Mena, E.; Carrió, I. & Barbanoj, M.J. 2006. Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant. Psychopharmacology 186 (1): 93–8.
   PubMed Web of Science ®Google Scholar
• Riba, J.; Valle, M.; Urbano, G.; Yritia, M.; Morte, A. & Barbanoj, M.J. 2003. Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics 306 (1): 73–83.
   PubMed Web of Science ®Google Scholar
• Sackler, A.M.; Weltman, A.S. & Owens, H. 1966. Endocrine and metabolic effects of lysergic acid diethylamide on female rats. Toxicology and Applied Pharmacology 9 (2): 324–30.
   Web of Science ®Google Scholar
• Sackler, A.M.; Weltman, A.S. & Sparber, S.B. 1963. Effects of lysergic acid diethylamide on the total leukocytes and eosinophils of the female rat. Nature 199: 1194–5.
   PubMed Web of Science ®Google Scholar
• Schultes, R.E. 1998. Antiquity of the use of New World hallucinogens. Heffter Review of Psychedelic Research 1: 1–7.
   Google Scholar
• Schultes, R.E. & Hofmann, A. 1992. Plants of the Gods: Their Sacred, Healing and Hallucinogenic Powers. Rochester, VT: Healing Arts Press.
   Google Scholar
• Stefulj, J.; Jernej, B.; Cicin-Sain, L.; Rinner, I. & Schauenstein, K. 2000. mRNA expression of serotonin receptors in cells of the immune tissues of the rat. Brain, Behavior, and Immunity 14 (3): 219–24.
   PubMed Web of Science ®Google Scholar
• Strassman, R.J. & Qualls, C.R. 1994. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic and cardiovascular effects. Archives of General Psychiatry 51 (2): 85–97.
   PubMed Web of Science ®Google Scholar
• Strassman, R.J.; Qualls, C.R. & Berg, L.M. 1996. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biological Psychiatry 39 (9): 784–95.
   PubMed Web of Science ®Google Scholar
• Szabo, A.; Kovacs, A.; Frecska, E. & Rajnavolgyi, E. 2014. Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. PLoS One 9 (8): e106533.
   PubMed Web of Science ®Google Scholar
• Tourino, M.C.; de Oliveira, E.M.; Bellé, L.P.; Knebel, F.H.; Albuquerque, R.C.; Dörr, F.A.; Okada, S.S.; Migliorini, S.; Soares, I.S. & Campa, A. 2013. Tryptamine and dimethyltryptamine inhibit indoleamine 2,3-dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cells. Cell Biochemistry and Function 31 (5): 361–4.
   PubMed Web of Science ®Google Scholar
• Van de Kar, L.D. & Blair, M.L. 1999. Forebrain pathways mediating stress-induced hormone secretion. Front Neuroendocrinology 20 (1): 1–48.
   PubMed Web of Science ®Google Scholar
• Weltman, A.S. & Sackler, A.M. 1966. Metabolic and endocrine effects of lysergic acid diethylamide (LSD-25) on male rats. Journal of Endocrinology 34 (1): 81–90.
   PubMed Web of Science ®Google Scholar